Intervention not reported
NEXUS · children (aged 0 to < 18 years) who underwent blunt trauma evaluation in the emergency department Index test: CDRs that compared the…
1 finding from 1 review
Intervention not reported
Canadian C‐Spine Rule · children (aged 0 to < 18 years) who underwent blunt trauma evaluation in the emergency department Index test: CDRs that compared the…
1 finding from 1 review
Intervention not reported
PECARN retrospective · children (aged 0 to < 18 years) who underwent blunt trauma evaluation in the emergency department Index test: CDRs that compared the…
1 finding from 1 review
Intervention not reported
Leonard de novo · children (aged 0 to < 18 years) who underwent blunt trauma evaluation in the emergency department Index test: CDRs that compared the…
1 finding from 1 review
Intervention not reported
PEDSPINE criteria · children (aged 0 to < 18 years) who underwent blunt trauma evaluation in the emergency department Index test: CDRs that compared the…
1 finding from 1 review
Intervention not reported
NICE CG56 · children (aged 0 to < 18 years) who underwent blunt trauma evaluation in the emergency department Index test: CDRs that compared the…
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in clinical relapse (at 52 weeks, HBI > 4) compared with biosimilar (low certainty).
1 finding from 1 review
Loss of clinical response (at 52 weeks, HBI change from baseline of less than 4 points and a total score of less than 7 points) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher loss of clinical response (at 52 weeks, HBI change from baseline of… compared with biosimilar (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
1 finding from 1 review
IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure
Anticipated high responders: higher showed no clear difference in IU vs 100 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in IU vs 100 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
225/200 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in 225/200 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 225 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in IU vs 225 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
Mortality before hospital discharge · ventilated preterm infants with failure of initial non‐invasive respiratory support
nHFV showed no clear difference in mortality before hospital discharge compared with nIPPV following failure of initial non‐invasive respiratory support (low certainty).
1 finding from 1 review
Endotracheal intubation To discharge · ventilated preterm infants with failure of initial non‐invasive respiratory support
It is very uncertain whether nHFV changes endotracheal intubation To discharge compared with nIPPV following failure of initial non‐invasive respiratory support (very low certainty).
1 finding from 1 review
Chronic lung disease · ventilated preterm infants with failure of initial non‐invasive respiratory support
nHFV showed no clear difference in chronic lung disease compared with nIPPV following failure of initial non‐invasive respiratory support (low certainty).
1 finding from 1 review
Death or chronic lung disease · ventilated preterm infants with failure of initial non‐invasive respiratory support
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · ventilated preterm infants with failure of initial non‐invasive respiratory support
nHFV showed no clear difference in intraventricular haemorrhage, Papile grade 3/4 compared with nIPPV following failure of initial non‐invasive respiratory support (low certainty).
1 finding from 1 review